Tokyo, Japan, Oct 17, 2005 - (JCNN) - Kyowa Hakko Kogyo and Mitsubishi Pharma have obtained approval of additional indication for their recombinant alteplase agents, ACTIVACIN for Injection by Kyowa Hakko Kogyo and GRTPA inj. by Mitsubishi Pharma, from the Ministry of Health, Labor and Welfare, as of October 11.
The respective agents are now available for the treatment of improving dysfunction caused by acute ischemic cerebrovascular disease (within the first three hours of onset).
The two agents, which were launched in Japan in May 1991, are based on a recombinant tissue plasminogen activator developed by US firm Genentech.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group